NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

Company Overview

NeuroSense Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration. By combining high-throughput screening with advanced medicinal chemistry and in vivo disease models, the company is advancing multiple small-molecule preclinical candidates toward Investigational New Drug (IND)-enabling studies. Key areas of focus include Alzheimer’s disease, Parkinson’s disease and other brain disorders linked to aging and cellular dysfunction.

Founded by a team of neuroscientists and drug-discovery experts, NeuroSense is headquartered in Tel Aviv, Israel, with research operations extending to the United States. The company has established collaborations with leading academic institutions and contract research organizations to support its pipeline development. NeuroSense’s executive leadership brings extensive experience in biotechnology and pharmaceutical development, positioning the firm to translate its innovative science into potential new treatments for patients worldwide.

Key Stats

• Today's Range: $0.81 to $0.87
• 50-Day Range: $0.69 to $0.95
• 52-Week Range: $0.63 to $2.60
• Volume: 83,193 shs
• Average Volume: 183,272 shs
• Market Capitalization: $25.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

NeuroSense Therapeutics Stock Analysis - MarketRank™

NeuroSense Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 256th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroSense Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NeuroSense Therapeutics has a consensus price target of $8.50, representing about 939.1% upside from its current price of $0.82.

Amount of Analyst Coverage

NeuroSense Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NeuroSense Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroSense Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroSense Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of NeuroSense Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

NeuroSense Therapeutics has a short interest ratio ("days to cover") of 3.75, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroSense Therapeutics has recently decreased by 12.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroSense Therapeutics does not currently pay a dividend.

Dividend Growth

NeuroSense Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

NeuroSense Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for NeuroSense Therapeutics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for NRSN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.04% of the stock of NeuroSense Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 4/07/2025
• Today: 5/18/2026
• Next Earnings (Estimated): 6/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRSN
• CIK: 1875091
• Web: www.neurosense-tx.com
• Phone: 972-9799-6183
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeuroSense Therapeutics: $8.50
• High Price Target: $14.00
• Low Price Target: $3.00
• Potential Upside/Downside: +929.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.31
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -16.52

Miscellaneous

• Outstanding Shares: 32,560,000
• Free Float: 23,636,000
• Market Cap: $26.89 million
• Optionable: Not Optionable
• Beta: 1.60